Divestment of the APAC business for ZAR 26.5 billion will significantly reduce debt and enhance balance sheet flexibility, with proceeds used to drive organic growth in pharma and manufacturing. GLP-1s and contract manufacturing are key future growth drivers.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.